In lung cancer, ATRA pretreatment can resist cisplatin resistance and can inhibit the proliferation of CD133 + cells induced by cisplatin resistance, suggesting that ATRA May inhibit genes related to stem cells [23]. The gene discussed is PROM1; the disease is lung carcinoma.